Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Raw Materials: 2018-2024

  • RedHill Biopharma's Raw Materials fell 38.04% to $513,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $513,000, marking a year-over-year decrease of 38.04%. This contributed to the annual value of $513,000 for FY2024, which is 38.04% down from last year.
  • Latest data reveals that RedHill Biopharma reported Raw Materials of $513,000 as of Q4 2024, which was down 38.04% from $828,000 recorded in Q4 2023.
  • RedHill Biopharma's Raw Materials' 5-year high stood at $3.0 million during Q4 2021, with a 5-year trough of $513,000 in Q4 2024.
  • In the last 3 years, RedHill Biopharma's Raw Materials had a median value of $828,000 in 2023 and averaged $1.0 million.
  • As far as peak fluctuations go, RedHill Biopharma's Raw Materials soared by 68.08% in 2021, and later slumped by 53.92% in 2023.
  • RedHill Biopharma's Raw Materials (Quarterly) stood at $1.8 million in 2020, then soared by 68.08% to $3.0 million in 2021, then slumped by 40.34% to $1.8 million in 2022, then tumbled by 53.92% to $828,000 in 2023, then crashed by 38.04% to $513,000 in 2024.
  • Its last three reported values are $513,000 in Q4 2024, $828,000 for Q4 2023, and $1.8 million during Q4 2022.